The third-generation aromatase inhibitors (AIs) (anastrozole, letrozole and exemestane) are widely used to treat estrogen receptor positive (ER +) breast cancer in postmenopausal patients in all stages of the disease [1–6]. Here, ESR1 is linked to breast carcinoma.